198 related articles for article (PubMed ID: 36398320)
1. Rilonacept and Other Interleukin-1 Inhibitors in the Treatment of Recurrent Pericarditis.
Goel A; Bandyopadhyay D; Malik AH; Gupta R; Frishman WH; Aronow WS
Cardiol Rev; 2023 Jul-Aug 01; 31(4):225-229. PubMed ID: 36398320
[TBL] [Abstract][Full Text] [Related]
2. Anti-interleukin-1 agents for pericarditis: a primer for cardiologists.
Imazio M; Lazaros G; Gattorno M; LeWinter M; Abbate A; Brucato A; Klein A
Eur Heart J; 2022 Aug; 43(31):2946-2957. PubMed ID: 34528670
[TBL] [Abstract][Full Text] [Related]
3. Paradigm Shift in Diagnosis and Targeted Therapy in Recurrent Pericarditis.
Dong T; Klein AL; Wang TKM
Curr Cardiol Rep; 2023 Sep; 25(9):993-1000. PubMed ID: 37458866
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune and Autoinflammatory Pericarditis: Definitions and New Treatments.
Bizzi E; Trotta L; Pancrazi M; Nivuori M; Giosia V; Matteucci L; Montori D; Brucato A
Curr Cardiol Rep; 2021 Jul; 23(9):128. PubMed ID: 34319478
[TBL] [Abstract][Full Text] [Related]
5. Rilonacept for the treatment of recurrent pericarditis.
Fava AM; Reyaldeen R; Lo Presti S; Goyal A; Akintoye E; Hughes D; Klein AL
Expert Opin Biol Ther; 2022 Jan; 22(1):7-16. PubMed ID: 34757872
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis.
Abadie BQ; Cremer PC
BioDrugs; 2022 Jul; 36(4):459-472. PubMed ID: 35639340
[TBL] [Abstract][Full Text] [Related]
7. Novel Pharmacotherapies for Recurrent Pericarditis: Current Options in 2020.
Tombetti E; Mulè A; Tamanini S; Matteucci L; Negro E; Brucato A; Carnovale C
Curr Cardiol Rep; 2020 Jun; 22(8):59. PubMed ID: 32562029
[TBL] [Abstract][Full Text] [Related]
8. Rilonacept and Anakinra in Recurrent Pericarditis: A Systematic Review and Meta-Analysis.
Affas ZR; Rasool BQ; Sebastian SA; Affas RS; Mohamadtahr SK; Saoor NH; Mohammad AN; Saoor GH; Husain BA; Touza R; Touza G; Amen S; Nazzaro W
Cureus; 2022 Nov; 14(11):e31226. PubMed ID: 36505131
[TBL] [Abstract][Full Text] [Related]
9. [Pericarditis].
Marques C; Cacoub P
Rev Prat; 2021 Jan; 71(1):79-83. PubMed ID: 34160952
[TBL] [Abstract][Full Text] [Related]
10. The Role of Rilonacept in Recurrent Pericarditis.
Presti SL; Elajami TK; Reyaldeen R; Anthony C; Klein AL
Heart Int; 2021; 15(1):20-25. PubMed ID: 36277322
[TBL] [Abstract][Full Text] [Related]
11. Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children.
Signa S; D'Alessandro M; Consolini R; Miniaci A; Bustaffa M; Longo C; Tosca MA; Bizzi M; Caorsi R; Mendonça LO; Pession A; Ravelli A; Gattorno M
Pediatr Rheumatol Online J; 2020 Jun; 18(1):51. PubMed ID: 32546242
[TBL] [Abstract][Full Text] [Related]
12. RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis.
Klein AL; Imazio M; Brucato A; Cremer P; LeWinter M; Abbate A; Lin D; Martini A; Beutler A; Chang S; Fang F; Gervais A; Perrin R; Paolini JF
Am Heart J; 2020 Oct; 228():81-90. PubMed ID: 32866928
[TBL] [Abstract][Full Text] [Related]
13. Advances in pharmacotherapy for acute and recurrent pericarditis.
Vecchié A; Del Buono MG; Mauro AG; Cremer PC; Imazio M; Klein AL; Abbate A; Dentali F; Bonaventura A
Expert Opin Pharmacother; 2022 Apr; 23(6):681-691. PubMed ID: 35311434
[TBL] [Abstract][Full Text] [Related]
14. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study.
Imazio M; Andreis A; De Ferrari GM; Cremer PC; Mardigyan V; Maestroni S; Luis SA; Lopalco G; Emmi G; Lotan D; Marcolongo R; Lazaros G; De Biasio M; Cantarini L; Dagna L; Cercek AC; Pivetta E; Varma B; Berkson L; Tombetti E; Iannone F; Prisco D; Caforio ALP; Vassilopoulos D; Tousoulis D; De Luca G; Giustetto C; Rinaldi M; Oh JK; Klein AL; Brucato A; Adler Y
Eur J Prev Cardiol; 2020 Jun; 27(9):956-964. PubMed ID: 31610707
[TBL] [Abstract][Full Text] [Related]
15. A Brief Overview of Recurrent Pericarditis Management and the Potential of Rilonacept as a New Therapeutic Option.
Gupta M; Kaul S; Velazquez GR; Bandyopadhyay D; Fonarow GC; Klein A; Ghosh RK
Am J Cardiovasc Drugs; 2022 Jan; 22(1):27-33. PubMed ID: 34008144
[TBL] [Abstract][Full Text] [Related]
16. The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment.
Lopalco G; Rigante D; Cantarini L; Imazio M; Lopalco A; Emmi G; Venerito V; Fornaro M; Frediani B; Nivuori M; Brucato A; Iannone F
Trends Cardiovasc Med; 2021 Jul; 31(5):265-274. PubMed ID: 32376492
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-1 Blockers for the Treatment of Recurrent Pericarditis: Pathophysiology, Patient-Reported Outcomes, and Perspectives.
Thomas GK; Bonaventura A; Vecchié A; van Tassell B; Imazio M; Klein A; Luis SA; Abbate A
J Cardiovasc Pharmacol; 2024 Jun; 83(6):503-510. PubMed ID: 37163222
[TBL] [Abstract][Full Text] [Related]
18. Emerging Therapies for Recurrent Pericarditis: Interleukin-1 inhibitors.
Lo Presti S; Elajami TK; Reyaldeen R; Anthony C; Imazio M; Klein AL
J Am Heart Assoc; 2021 Oct; 10(19):e021685. PubMed ID: 34569270
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of an interleukin-1β receptor antagonist (anakinra) in idiopathic recurrent pericarditis.
Scardapane A; Brucato A; Chiarelli F; Breda L
Pediatr Cardiol; 2013; 34(8):1989-91. PubMed ID: 23052671
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of Interleukin-1 Receptor Antagonists in Patients With Recurrent Pericarditis.
Khayata M; Shah NP; Verma BR; Giugni AS; Alkharabsheh S; Asher CR; Imazio M; Klein AL
Am J Cardiol; 2020 Jul; 127():184-190. PubMed ID: 32416963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
